<DOC>
	<DOCNO>NCT00850057</DOCNO>
	<brief_summary>Primary Objectives - To determine safety maximum tolerate dose ( MTD ) Adenovirus-CD154 ( Ad-ISF35 ) inject directly lymph node patient CLL SLL . Secondary Objectives - To determine monitor clinical biological response patient treated injection Ad-ISF35 . - To determine ISF35 work CLL/SLL patient ' cell .</brief_summary>
	<brief_title>Pharmacodynamic ( PD ) Study Intranodal Adenovirus-CD154 ( Ad-ISF35 ) Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL/SLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Diagnosis Bcell CLL/SLL include Lymphocytosis monoclonal Bcells coexpressing ≥ one Bcell marker ( CD19 , CD20 , CD23 ) CD5 peripheral blood lymph node AND Bone marrow ≥ 30 % mononuclear cell CLL/SLL phenotype . 2 . Presence least ONE single accessible AND palpable lymph node cervical , supraclavicular , axillary , inguinal region . The size lymph node must large 2x2 cm horizontal perpendicular ax . 3 . Intermediate High risk , poor prognosis CLL/SLL 4 . Indication treatment define NCI Working Group Guidelines : Massive ( i.e . &gt; 6 cm leave costal margin ) progressive splenomegaly OR Massive lymph node nodal cluster ( i.e . &gt; 10 cm long diameter ) , progressive lymphadenopathy OR Grade 2 3 fatigue OR Fever ≥ 100.5˚F night sweat great 2 week without documented infection OR Presence weight loss ≥ 10 % precede 6 month OR Progressive lymphocytosis increase ≥ 50 % 2month period anticipate doubling time le 6 month . Evidence progressive marrow failure manifest development , worsen , anemia / thrombocytopenia . Autoimmune anemia / thrombocytopenia poorly responsive corticosteroid therapy . 5 . Males females 18 year age old 6 . Laboratory parameter specify : Hematologic : Hemoglobin ≥ 10 g/dL ( may posttransfusion ) ; platelet count ≥ 50 x103/mm3 Hepatic : Total Bilirubin &lt; 2 X ULN , ALT AST &lt; 2 x ULN Renal : Creatinine ≤ 2 X ULN 7 . ECOG Performance Status ≤ 2 8 . Anticipated survival least 3 month 9 . For men woman childproducing potential , use effective barrier contraceptive method study one month follow treatment . 10 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 11 . Negative test result current/active infection HIV1 , HIV2 , HTLV1 , HTLV2 , hepatitis A , B , C within 30 day registration . ( Antibody , antigen nucleic acid test acceptable , depend institutional standards. ) . 1 . Pregnant nursing woman 2 . Treatment chemotherapy monoclonal antibody within 28 day prior enter study . 3 . Treatment chemotherapy monoclonal antibody time participation trial . 4 . Grade 3 4 cardiac disease define New York Heart Association Functional Classification 5 . Severe debilitate pulmonary disease ( dyspnea rest , significant shortness breath , COPD ) 6 . Participation investigational drug study within 28 day prior ISF35 administration . ( Patient must recover acute effect previously administer investigational agent ) 7 . History malignancy CLL within five year registration , except patient adequately treat basal , squamous cell carcinoma localize cervical cancer . 8 . Active symptomatic fungal , bacterial and/or viral infection include active HIV viral ( A , B C ) hepatitis . 9 . Any illness condition opinion Investigator may affect safety treatment evaluation study 's endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>